NCI has launched a resource for cancer researchers interested in conducting studies using specimens and clinical data collected from cancer treatment trials in NCI's National Clinical Trials Network and former NCI Cooperative Group Program.
Boehringer Ingelheim and OSE Immunotherapeutics announced a worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist targeting myeloid lineage cells.
FDA granted an accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia who are in remission but still have minimal residual disease.
Seattle Genetics Inc. and Astellas Pharma Inc. said FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate, for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors.
Hologic, Inc. said the Clarity HD high-resolution 3D imaging and Intelligent 2D imaging technology has received PMA approval from FDA and are now available on the 3Dimensions breast tomosynthesis system.
Bristol-Myers Squibb Co. said FDA has accepted its supplemental Biologics License Application for Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for the treatment of adults with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
Novartis announced the FDA has expanded the indication for Tasigna (nilotinib) to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.
FDA approved Adcetris (brentuximab vedotin) for adult patients with previously untreated stage III or IV classical Hodgkin lymphoma in combination with chemotherapy.
The University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center is now certified to offer CAR-T cell therapy.
FDA has granted Breakthrough Therapy Designation for erdafitinib in the treatment of urothelial cancer.
